China SXT Pharmaceuticals, a pharmaceutical ingredients company specialising in TCMPs (Traditional Chinese Medicine Pieces), has received a pharmaceutical manufacturing permit from Jiangsu Province Medical Products Administration for lyophilisation processing, after passing a compliance inspection at its production facility.
Lyophilisation processing, also known as freeze drying, is a process of freezing raw materials or products and removing the frozen water by sublimation (the ice turns directly into vapour without the liquid phase in the vacuum). After the lyophilisation process, the raw materials or products become loose and fragile, which remarkably improves their aqueous solubility. The dehydrated raw materials and products also have an extended shelf life. More importantly to China SXT, the process is helpful in the manufacturing of products that contain temperature-sensitive components as they are kept in a frozen and dry condition and remain unchanged.
The manufacture of the company's oral medicinal product, Luxuejing, involves the lyophilisation process. "This permit for new production scope of lyophilisation processing will contribute significantly to our continuous effort in leading research and development of new advanced TCMPs and pursuit of higher quality of the products. We believe it will further accelerate our R&D of new Advanced TCMPs, which is expected to expand our market share for the advanced Directly-Oral TCMP and After-Soaking-Oral TCMP products," said Feng Zhou, CEO of China SXT.
